Although the current animal models of T2DM are limited by their ability to recapitulate the impact of diabetes on bone metabolism, the data available are largely consistent with those obtained in human studies27, suggesting that insulin-induced bone impairment may play a role in the elevated serum FGF23 levels in the first-degree relatives of patients with diabetes. This evidence concerns the gene FGF23 and diabetes mellitus.